PLETHICO PHARMACEUTICALS LIMITED

PLETHICO PHARMACEUTICALS LIMITED
www.plethico.com
Corporate Presentation
H1 CY 2009
!
"
#
!
$
!
$
"
$!
$
$
!
!
!
!
%
!
!
!
"
&
&
$
'
'
&
!
!
$
!
(
(
(
(
Plethico
Group
Overview
()
&
(
!
!1 *0
(2
4
!
1
,
!"
./ .0 "
./ .0
/3"
*
0
/
+
#
$
(5
()
(9
(
;<=
'
8
'
% &
6
'7 8 !
1
1
!
!
#
%"'&: &
&8
2 : &8 =;>
!6 5
./2 ;? 9
1
3
!
>@?
1 <@>
(
( 6
( 9
&
!
&
<>AB
D
/
(
( 2
!
C
!
! C
& * +/
9
!
5
./
.0
"
?EBBB
"
!
: 985
!
!
8
)*
(
!
( 6
( 8
( "C
<>>;
C
/ 6
"
!F
&
G
=BB;
9
+
*
,
$
.
$
*
) 0
1
*
-
2 "
!
" !
*
" #! ,
9
/""'
H
33.
"
" # 5
!
" #
!
+ 2 4(
,
8 !
!
!
!
!
F !
6".
$
%
/
!
!
$
)
"
7
+ 25 8 !
#
!
!
&
:
!
!
!
!
EI
=BBA
H
3"
(
)
0) 7
/""
.
$
*
) -
(
&
;B
!
)*
/""'
38.
!
C
&
G
3.
=BB;
2-
!
J?
!
!
9
9
*
!
!
( :+
<>
4
)
!
6.
?BI
K<
C
&
&
=BB@
!
<>>A
!
K<
C
8.
!
2
!+
$
6
&
C
!
=BBA
&
! !
C
./
=BB@
33
!"$
/""'*
2
2
; 0*
7
(
#
3&
9
9
:
&
98-
L6
India
10%
/
Africa
10%
4,
9
:
9 +& #
5
US & Regulated
markets
:
44%
L6
*
9
"
/
9
"
Third Front
23%
F
<=
"
<@"
@
?/3
3
CIS
13%
1
(
$
9
<
-
!
(
:
9
"
*
!
F
1
,
1
) =
<
7
<
=
7
;
7
2
3/
-
!
!
!
!!
!
!
C
!
&
C
>
4
C
'
!
2
!
2
7
=
7
'
!
&
"
F
'
1=
!
!
'
# !
!
+
+
!3
3
/
"
9'
3
<BBB
-
&
=BB
)
?
<
./62"
#
3888& 9
.09*8"
)
<
?
#
/""3& 9
,9 !
?
#
38'@& 9
– 5
+
'
– 5
<$
'
/3M
F !
2
)
'
!
2 #
/""8& )
9
!
,
$
"
./ 3
$
' !
&
!
&
,9 !
36
GROUP
A TRULY GLOBAL REACH
Qatar
Saudi
Arabia
USA*
El Salvador
Nicaragua
Costa Rica
Panama
Guatemala
Turkmenistan
Ukraine
Uzbekistan
Russia
Tajikistan
Kazakhstan
Kyrgyzstan
Moldova
Azerbaijan
Georgia
KuwaitUK*
Yemen
CHINA*
Dubai
Bahrain
Cameroon
Oman
Sierra Leone
Caribbean
Jordan
Trinidad & Tobago Algeria
Sudan
Domnican Republic
Sri
Ivory Coast Uganda
Peru
Lanka
DR Congo
Chile
Kenya
Benin
Ecuador
Ethiopia
Togo
Eritrea
Colombia
Burkina Faso South Africa
Venezuela
Botswana
Nigeria
Braza Congo Tanzania
Gabon
Ghana
Senegal
* Denotes areas due to
acquisition of NATROL INC,
USA
Vietnam
Papua New Guinea
Malaysia
Cambodia
Philippines
Hong Kong
Thailand
Singapore
Indonesia
Taiwan
Korea AUST. &
Myanmar NZ*
Business
Delivery
(&
"
(&
+9
!
1
&
Focus
currently US, now shifting to ROW
(9
1"
Focus currently ROW, shifting to US
& UK
2
Food Supplement Range
Cough & Cold Range
A
Effervescent Range-NDDS
(
3
(/
#)
"
N6
* F"
9
(,
(&
9
N6
N6
*
F
2
21
Sells into
DRUG STORE
B6<
"""
CLUB/MM
GYMS
2
;
E-Commerce
HEALTH FOOD
* $1*D
CATALOGS
(
(
*
C
C
+
22
Analysis of
Financials
Key Financial Indicators (Current) H1 2009
Consol. Revenues at INR 536 Crores and
PAT (before extraordinary item) at INR 63
Crores.
Regional contribution: US & EU 43%,
Third front (LAC/SEA/GCC) 21%, CIS
11%, Africa 7%, Tricon UAE 13% & India
5%.
Herbal/ Nutraceuticals 80%.
Debt at approx 300 Crore excluding FCCB.
(All figs in INR)
Summary
+
(
2
?
$
!
2
98-+
2
& *
! +
/
!
+/
9
!
5
5
!
!
!!
5
"
+
6
+
!
!
!
!
C
7
-
2
./
! !
!!
3
!
'
!
+
"
"
-
./
/3"
.0 * !0 ! 8
+/
N
2
!
( 2
9
0
2
( :
&
!
!
-8
812
&
!
/!
/ $
6
)
9